ECSP12005525A - TYROSINE KINASE INHIBITORS - Google Patents
TYROSINE KINASE INHIBITORSInfo
- Publication number
- ECSP12005525A ECSP12005525A ECSP12005525A ECSP12005525A EC SP12005525 A ECSP12005525 A EC SP12005525A EC SP12005525 A ECSP12005525 A EC SP12005525A EC SP12005525 A ECSP12005525 A EC SP12005525A
- Authority
- EC
- Ecuador
- Prior art keywords
- disease
- compounds
- tyrosine kinase
- kinase inhibitors
- stipulated
- Prior art date
Links
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a compuestos de la fórmula (I) en donde los sustituyentes R1, R2, y R4 tienen el significado estipulado y explicado en la descripción de la invención, a procesos para la preparación de estos compuestos, a composiciones farmacéuticas que los contienen, al uso de los mismos opcionalmente en combinación con uno o más compuestos farmacéuticamente activos diferentes, para la terapia de una enfermedad que responda a la inhibición de la actividad de la cinasa de proteína, en especial una enfermedad neoplástica, en particular leucemia, y a un método para el tratamiento de esta enfermedad.The invention relates to compounds of the formula (I) wherein the substituents R1, R2, and R4 have the meaning stipulated and explained in the description of the invention, to processes for the preparation of these compounds, to pharmaceutical compositions containing them. , to the use thereof optionally in combination with one or more different pharmaceutically active compounds, for the therapy of a disease that responds to the inhibition of protein kinase activity, especially a neoplastic disease, in particular leukemia, and a method for the treatment of this disease.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0215676.8A GB0215676D0 (en) | 2002-07-05 | 2002-07-05 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP12005525A true ECSP12005525A (en) | 2014-01-31 |
Family
ID=52784804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP12005525 ECSP12005525A (en) | 2002-07-05 | 2012-09-24 | TYROSINE KINASE INHIBITORS |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP12005525A (en) |
-
2012
- 2012-09-24 EC ECSP12005525 patent/ECSP12005525A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP055525A (en) | TYROSINE KINASE INHIBITORS | |
| ECSP067076A (en) | DERIVATIVES OF PIRIMIDINA UREA AS INHIBITORS OF QUINASA | |
| ECSP055701A (en) | NEW DERIVATIVES OF PYRIMIDINAMIDE AND THE USE OF THE SAME | |
| UY27604A1 (en) | CHEMICAL COMPOUNDS. | |
| ECSP056194A (en) | DERIVATIVES OF PIRAZOLO-QUINAZOLINA, PROCEDURE FOR ITS PREPARATION AND ITS USE AS QUINASA INHIBITORS | |
| EE200300475A (en) | Tyrosine kinase inhibitors, pharmaceutical compositions containing them, and said compounds for use in the treatment of diseases | |
| NO20053470L (en) | Triazolopyridazines as protein kinase inhibitors | |
| SE0202463D0 (en) | Novel compounds | |
| ECSP034774A (en) | PIRAZOLOPIRIMMIDINAS AS THERAPEUTIC AGENTS | |
| ECSP034773A (en) | PIRAZOLOPIRIMMIDINAS AS THERAPEUTIC AGENTS | |
| TR200201505T2 (en) | Pirazolopyrimidines as therapeutic agents | |
| NO20071915L (en) | Diaminotriazole compounds useful as protein kinase inhibitors | |
| ATE371656T1 (en) | HETEROARYL-PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | |
| ATE430747T1 (en) | 2-PYRIMIDINYL-PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | |
| NO20060398L (en) | Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for the treatment and inhibition of cancer | |
| NO20055863L (en) | W-carboxyaryl-substituted diphenylurea compounds as raf kinase inhibitors | |
| BRPI0417717A (en) | compound, pharmaceutical composition, and use of a compound | |
| ECSP045004A (en) | INHIBITORS OF THE 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3 FOR THE TREATMENT OF DEPENDING ANDROGEN DISEASES | |
| IS6491A (en) | Pteridine compounds for the treatment of psoriasis | |
| DE60314623D1 (en) | SUBSTITUTED PYRAZOLOPYRIMIDINES | |
| BR0309342A (en) | Compound, pharmaceutical composition, use of a compound, and method of treating or prophylaxis of human diseases or conditions. | |
| SE0101932D0 (en) | Pharmaceutical combinations | |
| BR0316458A (en) | Compound, pharmaceutical composition, method of treating or preventing disease, method for enhancing cognition in a healthy patient, and use of a compound | |
| BRPI0515721A (en) | use of a src kinase inhibitor and a bcr-abl inhibitor, pharmaceutical composition and combination | |
| NO20014855L (en) | N- (2-phenyl-4-aminobutyl) -1-naphthamides as neurokinin-1 receptor antagonists |